Please try another search
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Name | Age | Since | Title |
---|---|---|---|
James L. M. Ferrara | - | - | Clinical Advisor |
Mohamad Mohty | - | - | Clinical Advisor |
Clifford S. Deutschman | - | - | Clinical Advisor |
Abraham Havron | 76 | 2014 | Independent Director |
Paul J. Martin | - | - | Clinical Advisor |
Gili Hart | 49 | 2014 | Independent Director |
Shai Novik | 58 | 2014 | Executive Chairman |
Brian Schwartz | 62 | 2020 | Director |
Mitchell M. Levy | - | - | Clinical Advisor |
Andrew E. Singer | 53 | 2023 | Independent Director |
Roger James Pomerantz | 67 | 2022 | Independent Vice Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review